One source of relief for moderate to severe acute pain
NUCYNTA®, designed as a novel short-acting opioid, offers the same active molecule as NUCYNTA® ER (tapentadol) extended-release tablets, CII

Powerful Efficacy



See phase 3 data demonstrating the strength of NUCYNTA® for patients with moderate to severe acute pain.

LEARN MORE

CO‑PAY SAVINGS
AVAILABLE



Learn about our co‑pay savings offer for your commercially-insured patients.

LEARN MORE